XML 23 R9.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Note 3 - Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information | 12 Months Ended
--- | ---
Dec. 31, 2018
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | 3. Revenue by Product Group, by Significant Customer and by Geographic Location; Geographic Information Product revenue by product group is as follows:
|  | Years Ended December 31,
|  | 2018 |  | 2017 |  | 2016
|  | Revenue |  | Percentage of Product Revenue |  | Revenue |  | Percentage of Product Revenue |  | Revenue |  | Percentage of Product Revenue
Orthobiologics |  | $ | 93,556 |  |  |  | 89 | % |  | $ | 93,816 |  |  |  | 87 | % |  | $ | 89,695 |  |  |  | 87 | %
Dermal |  |  | 396 |  |  |  | 0 | % |  |  | 2,755 |  |  |  | 3 | % |  |  | 2,759 |  |  |  | 3 | %
Surgical |  |  | 5,514 |  |  |  | 5 | % |  |  | 5,262 |  |  |  | 5 | % |  |  | 5,427 |  |  |  | 5 | %
Other |  |  | 6,065 |  |  |  | 6 | % |  |  | 5,950 |  |  |  | 5 | % |  |  | 5,051 |  |  |  | 5 | %
|  | $ | 105,531 |  |  |  | 100 | % |  | $ | 107,783 |  |  |  | 100 | % |  | $ | 102,932 |  |  |  | 100 | %
Product revenue from the Company’s sole significant customer, Mitek, as a percentage of the Company’s total product revenue was 73%, 73%, and 75% for the years ended December 31, 2018, 2017, and 2016, respectively. ORTHOVISC became available for sale in the United States on March 1, 2004, and it is marketed exclusively by Mitek under the terms of an initial ten -year licensing, distribution, supply, and marketing agreement entered into in December 2003. The agreement was extended by Mitek for additional five -year terms in 2012 and in 2017, with the current agreement to expire on December 20, 2023. In December 2011, the Company entered into a fifteen -year licensing agreement with Mitek to exclusively market MONOVISC in the United States. The agreement provides certain milestone payments to the Company when rolling end-user sales of U.S. MONOVISC exceed certain target sales goals. For the years ended December 31, 2018, 2017, and 2016, the Company recognized milestone revenue of $0.0 million, $5.0 million, and $0.0 million, respectively. The milestone revenue of $5.0 million in 2017 was as a result of MONOVISC achieving end-user sales in 2017 of $100 million within a consecutive 12 -month period in the United States. Total revenue by geographic location based on the location of the customer in total and as a percentage of total revenue are as follows:
|  | Years Ended December 31,
|  | 2018 |  | 2017 |  | 2016
|  | Total Revenue |  | Percentage of Revenue |  | Total Revenue |  | Percentage of Revenue |  | Total Revenue |  | Percentage of Revenue
Geographic Location: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
United States |  | $ | 85,351 |  |  |  | 81 | % |  | $ | 92,905 |  |  |  | 82 | % |  | $ | 83,972 |  |  |  | 81 | %
Europe |  |  | 11,730 |  |  |  | 11 | % |  |  | 12,435 |  |  |  | 11 | % |  |  | 10,953 |  |  |  | 11 | %
Other |  |  | 8,474 |  |  |  | 8 | % |  |  | 8,080 |  |  |  | 7 | % |  |  | 8,454 |  |  |  | 8 | %
Total |  | $ | 105,555 |  |  |  | 100 | % |  | $ | 113,420 |  |  |  | 100 | % |  | $ | 103,379 |  |  |  | 100 | %
On May 2, 2018, the Company publicly disclosed a voluntary recall of certain production lots of its HYAFF-based products, HYALOFAST, HYALOGRAFT C, and HYALOMATRIX. The Company initiated the voluntary recall after internal quality testing, which indicated that the products were at risk of not maintaining certain measures throughout their entire shelf life. While there was no indication of any safety or efficacy issue related to the products at the time, the Company removed the products from the field as a precautionary measure. During the three -month period ended March 31, 2018 the Company recorded a revenue reserve for this voluntary recall of $1.1 million of which $0.9 million was related to revenue recorded in prior periods. The adjustments related to the initial revenue reserve subsequent to March 31, 2018 were immaterial. The revenue reserves impacted Dermal and Orthobiologics product groups and all geographic locations. Net long-lived assets, consisting of net property and equipment, are subject to geographic risks because they are generally difficult to move and to effectively utilize in another geographic area in a reasonable time period and because they are relatively illiquid. Net tangible long-lived assets by principal geographic areas are as follows:
|  | Years Ended December 31,
|  | 2018 |  | 2017
United States |  | $ | 51,385 |  |  | $ | 52,828 |
Italy |  |  | 2,726 |  |  |  | 3,355 |
Total |  | $ | 54,111 |  |  | $ | 56,183 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration